Valeant Pharmaceuticals PT Raised to $162.00 (VRX)
Analysts at BMO Capital Markets hoisted their price target on shares of Valeant Pharmaceuticals (NYSE:VRX) from $149.00 to $162.00 in a research report issued to clients and investors on Wednesday, AnalystRatings.NET reports. BMO Capital Markets’ price objective indicates a potential upside of 10.60% from the stock’s previous close.
Shares of Valeant Pharmaceuticals (NYSE:VRX) opened at 146.47 on Wednesday. Valeant Pharmaceuticals has a 52 week low of $64.05 and a 52 week high of $147.20. The stock has a 50-day moving average of $133.1 and a 200-day moving average of $112.6. The company’s market cap is $48.905 billion.
A number of other firms have also recently commented on VRX. Analysts at UBS AG raised their price target on shares of Valeant Pharmaceuticals from $125.00 to $141.00 in a research note on Wednesday, January 8th. They now have a “buy” rating on the stock. Separately, analysts at TD Securities downgraded shares of Valeant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Finally, analysts at Ladenburg Thalmann raised their price target on shares of Valeant Pharmaceuticals from $123.00 to $155.00 in a research note on Wednesday, January 8th. They now have a “buy” rating on the stock. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $129.03.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.